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Plasma Angiotensins, Renin, and Blood 
Pressure During Acute Renin Inhibition by 
CGP 38 560A in Hypertensive Patients 
Xavier Jeunemattre, Joel Menard, Jurg Nussberger, Tarn T. Guyene, Hans R. Brunner, and 
Pierre Corvol 
The n e w renin inhibitor C G P 3 8 5 6 0 A has b e e n 
shown to block angiotensin (ANG) product ion in 
healthy volunteers . In order to d e t e r m i n e its 
potential ant ihyper tens ive effect, the c o m p o u n d 
was adminis tered in a 3 0 - m i n infusion, in 12 
hypertensive pat ients (mean blood pressure (BP): 
112.8 ± 3.5 m m Hg). T h e s e pat ients w e r e selected 
for their sensit ivity to captopril : a single oral dose 
of 50 m g captopril l o w e r e d their m e a n BP b y 
8.8 ± 2.2 m m Hg after 30 m i n a n d b y 15.3 ± 
1.5 m m Hg after 90 m i n . At the end of the renin 
inhibitor infusion, m e a n blood pressure decreased 
by 5.7 ± 2.2 m m Hg in the six pat ients infused w i t h 
the dose of 0.125 m g / k g a n d b y 6.0 ± 1.8 m m Hg in 
the six pat ients infused w i t h 0.250 m g / k g . T h e fall 
in blood pressure w a s correlated to t h e initial 
plasma renin act ivity (PRA) (r = 0.61, Ρ < .05). A 
dose-dependent effect w a s observed on p l a s m a 
ANG I w h i c h fell b y 74% w i t h 0.125 m g / k g a n d b y 
94% with 0.250 m g / k g . Identical falls w e r e found 
for p l a s m a A N G II (72% a n d 94%, respect ively) and 
A N G I and A N G II w e r e wel l correlated (r = 0.91, 
Ρ < .001). T h e fall in BP w a s correlated to t h e fall in 
p l a s m a A N G I (r = 0.77, Ρ < .01). T h e t ime-course 
of the BP changes w a s paral lel to t h e changes in 
p l a s m a angiotensins , as w e r e t h e sl ightly delayed 
rise a n d fall in act ive renin m e a s u r e d b y a direct 
i m m u n o r a d i o m e t r i c assay. W h e n m e a s u r e d b y the 
convent ional A N G I r a d i o i m m u n o a s s a y , P R A 
values indicated a long-last ing inhibit ion. T h e ar te -
factual n a t u r e of the latter result is demonst ra ted 
b y the different results obtained w i t h an A N G I 
ant ibody- t rapping r a d i o i m m u n o a s s a y , w h i c h 
fol lowed m o r e closely p l a s m a A N G I levels . A m J 
H y p e r t e n s 1989; 2 : 8 1 9 - 8 2 7 
K E Y W O R D S : R e n i n inhibit ion, p l a s m a renin 
activity, p l a s m a angiotensins , blood pressure , 
convert ing e n z y m e inhibit ion, act ive renin . 
Th e goal of research on renin inhibition is to achieve a more specific b lockade of the renin-angiotensin system (RAS) than is possible with angiotensin converting enzyme (ACE) inhibi­
tion. Indeed, renin is an enzyme which acts on a unique 
substrate, angiotensinogen, whereas converting en­
zyme splits several substrates, including bradykinin, 
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which m a y e n h a n c e the efficacy of this therapeutic ap­
proach to hypertension and congestive heart failure, 
and m a y also cause some of its s ide-effects . 1 It is also 
expected that the clinical use of renin inhibitors will 
provide a better tool than A C E inhibitors for investigat­
ing the contribution of the R A S to the regulation of 
b lood pressure and general hemodynamics . T h e angio­
tensin II ( A N G II) antagonist , saralasin, and the A C E 
inhibitor, teprotide, were the first pharmacological tools 
used for this purpose. Depending on the prevailing 
plasma renin activity (PRA) , their hypotensive effects 
were substantially different . 2 T h e y both lowered b lood 
pressure more w h e n the prevailing P R A was high; over-
© 1989 by the American Journal of Hypertension, Inc. 0895-7061/89/$3.50 
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all, teprotide was more effective. T h e superiority of the 
A C E inhibitor over the A N G II antagonist w a s ex-
plained by the partially agonistic properties of saralasin, 
and possibly by the additional effects of the A C E inhibi-
tor on several vasoactive mechanisms outside of the 
R A S . Renin inhibitors should help in evaluating more 
specifically the renin contribution to hypertension, but 
they m a y also have their o w n limitations, as already 
suggested by animal exper iments . 3 ' 4 
T h e present study was designed to study the efficacy 
and potency of the recently synthesized renin inhibitor 
C G P 3 8 5 6 0 A in hypertensive patients w h o responded 
favorably to captopril . C G P 3 8 5 6 0 A is a potent , low-
molecular-weight , h u m a n renin inhibi tor , 5 which has 
b e e n s h o w n to decrease b lood pressure of marmosets , 
and to be well tolerated b y normal volunteers main-
tained on a normal sodium diet 6 or after mild sodium 
deplet ion. 7 
M E T H O D S 
P a t i e n t s Twelve hypertensive patients w h o s e blood 
pressures ranged from 1 6 6 / 1 0 8 to 1 9 0 / 1 3 0 m m Hg at 
their first visit to the Hypertension Clinic were studied. 
All were hospitalized. T h e y h a d b e e n selected according 
to the effects on blood pressure of a single oral adminis-
tration of captopri l . 8 
This captopril test was performed at 8 :00 A M , after 
6 0 min rest in the supine position, 1 to 4 days before the 
renin-inhibitor infusion. T h e patients received a single 
oral dose of 5 0 mg of captopril . Their m e a n arterial 
b lood pressure ( M A B P ) was monitored every 5 min b y 
an automatic device (oscillometric method , Sentron) 
and was analyzed be t ween 3 0 min before and 9 0 min 
after administration of captopril . T h e patients were se-
lected for C G P 3 8 5 6 0 A infusion if their M A B P before 
captopril w a s 1 1 0 m m Hg a n d if higher or their b lood 
pressure fell by 10 m m Hg or more be tween 60 and 
9 0 min after captopril intake. A blood sample for renin 
and aldosterone measurements was drawn before and 
9 0 min after the captopril administration. 
O f the 12 patients included in our study, all but one 
were Caucasians . Their m e a n age w a s 3 8 ± 12 years. 
T h e y h a d n o renal or hepatic insufficiency, n o protein-
uria a n d n o previous history of cardiovascular disease. 
Five of them h a d a unilateral renal artery stenosis, two a 
unilateral segmental renal hypoplasia and five essential 
hypertension. Bilateral kidney disease, primary aldos-
teronism and pheochromocytoma were excluded by the 
usual tests. 
S t u d y Protoco l All patients were mainta ined on a daily 
sodium intake of 1 0 0 m m o l daily for at least 3 days prior 
to the study. T h e study protocol was approved by the 
Broussais Hospital Ethics Commit tee , and all patients 
gave their in formed consent , in writing. All drugs, in-
cluding antihypertensive agents, were withdrawn at 
least one week prior to the start of the study, except for 
one patient w h o received nifedipine until 24 h before 
the captopril test. 
Patients were recumbent w h e n a catheter was in-
serted in the antecubital vein at 8 :00 A M . B lood pressure 
was monitored every 5 min for 2 0 min, a n d then at 
2 -min intervals for 10 min prior to the start of the 30-
min intravenous infusion of the renin inhibitor, C G P 38 
5 6 0 A (time 0 ) . T h e measurements at 2 -min intervals 
were maintained for another 30 min and then blood 
pressure was measured at 5 -min intervals for 9 0 min. 
C G P 3 8 5 6 0 A was infused via the catheter a n d blood 
samples were drawn from a venous catheter inserted in 
the other arm. C G P 3 8 5 6 0 A was infused at a constant 
rate over 3 0 min, the total dose being diluted in 125 ml 
isotonic 5 % glucose. 
Six patients (average age: 39 ± 16 years; average 
M A B P : 1 1 0 ± 11 m m Hg) each received a cumulative 
dose of 0 .125 mg/kg and the other six of cumulative 
dose of 0 . 2 5 0 mg/kg (average age: 3 8 ± 6 years ; aver-
age M A B P 115 .5 ± 13 m m Hg) . A second captopril test 
was performed the day after the infusion of the renin 
inhibitor in 4 patients w h o h a d received 0 . 1 2 5 mg/kg of 
the renin inhibitor and in 3 patients w h o h a d received 
0 . 2 5 0 mg/kg. T h e purpose of the second test was to 
el iminate the order effect in the comparison between the 
effects of captopril and the renin inhibitor on blood 
pressure. 
A s s a y s T h e methods of plasma renin measurement are 
s h o w n in Table 1. P lasma renin activity (PRA) was mea-
sured by a A N G I radioimmunoassay: the in vitro rate of 
angiotensin I ( A N G I) generation during incubation of 
TABLE 1. METHODS OF PLASMA RENIN 
MEASUREMENT 
Plasma Renin Activity (PRA) 
This conventional method measures, by radioimmunoassay, 
the ANG I generated in plasma during a defined incubation. 
During the incubation, degradation of generated ANG I is 
prevented by chemical inhibitors added to the plasma prior to 
the incubation. 9 
Plasma Renin Activity (PRT-TA) 
This method measures, by radioimmunoassay, the ANG I 
generated in plasma during a defined incubation. During the 
incubation, degradation of generated ANG I is prevented by 
the anti-ANG I antibodies used in the subsequent radioimmu-
noassay, which are added to the plasma in a high concentra-
tion, prior to the incubation, and which trap ANG I . 1 0 
Plasma Active Renin 
(immunoradiometric assay—IRMA) (AR) 
This method measures the concentration of active renin mole-
cules in plasma, in a sandwhich assay using two monoclonal 
antibodies. The first antibody traps active and inactive renins 
and the second—iodinated—antibody binds to an epitope 
specific for active renin. This measurement is independent of 
the enzymatic activity of renin. 1 1 
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endogenous renin and angiotensinogen in plasma at 
pH 5.7 , at 3 7 ° C , for 9 0 min, was determined by the 
method of Sealey et a l . 1 9 It was also evaluated by an 
enzymat ic/ANG I trapping assay ( P R A - T A ) according 
to Poulsen and J o r g e n s e n . 1 0 Active immunoreact ive 
renin (AR) was measured by an immunoradiometr ic 
assay according to M e n a r d et a l . 1 1 T h e monoclonal anti­
body used to detect active renin specifically recognizes 
an epitope of active renin and does not cross-react with 
inactive renin which is devoid of this recognition site. In 
all 12 patients, before and after captopril ingestion and 
before the renin inhibitor infusion, all measurements of 
renin were closely correlated ( P R A ν P R A - T A : r = 0 .78 , 
η = 12, Ρ < . 0 1 ; P R A ν AR: r = 0 . 9 3 5 , η = 3 6 , Ρ < . 0 0 1 ; 
P R A - T A ν AR: r = 0 .68 , η = 12, Ρ = .01 ) . Aldosterone 
was measured after extraction from plasma by the 
method of P h a m and C o r v o l . 1 2 
For the measurements of plasma A N G I and A N G II, 
C G P 3 8 5 6 0 A was added to all tubes, according to 
Nussberger et a l . 1 3 P lasma A N G I was measured after 
immediate centrifugation of b lood and extraction of 
plasma on a phenylsil ica column (Bondelut P H ) . A very 
sensitive assay was set up for A N G I which is able to 
detect 0.5 f m o l / m L - 1 . T h e 5 0 % displacement of the 
iodinated tracer in the standard curve is obtained with 7 
fmol/tube of A N G I. For plasma A N G II measurement , 
plasma samples were stored at — 8 0 ° C for 1 to 3 m o n t h s 
after the clinical investigation. After rapid thawing, they 
were extracted on Bondelut P H and the extract was puri­
fied on H P L C according to Nussberger et a l . 1 4 In the 
stored plasma samples of two patients A N G I was gen­
erated, due to inadequate conditions during transporta­
tion, despite the presence of the renin inhibitor. T h e 
corresponding A N G II concentrat ions indicated m a s ­
sive in vitro generation of A N G II and the values were 
therefore excluded from the analysis. 
S ta t i s t i ca l A n a l y s i s T h e results are reported as 
m e a n s ± S E M . T h e y were analyzed by nonparametr ic 
tests using the Kruskal-Wallis and Friedman tests for the 
analysis of variance, the Wilcoxon test for matched 
paired data and the Spearman rank coefficient for cor­
relations. T h e level of significance was Ρ < .05 . 
R E S U L T S 
I n f l u e n c e of C a p t o p r i l o n B l o o d P r e s s u r e a n d R e n i n -
A n g i o t e n s i n S y s t e m According to the protocol, the 12 
patients selected h a d a marked fall in m e a n b lood pres­
sure be tween 60 and 9 0 min after captopril intake: 
15 .3 ± 1.5 m m Hg, (P < . 0 0 1 ) . Table 2 shows the re­
sults of the captopril test for each subgroup of 6 patients 
and also compares their results with the captopril test 
performed in 7 patients 24 h after the renin inhibitor 
infusion. P R A increased from 3.8 ± 1.4 to 2 0 . 6 ± 9 .6 
n g / m L / h (P < .001) after captopril and A R (active 
renin) rose by 2 1 5 % ± 9 0 . A R after captopril was corre­
lated to the initial A R levels (r = 0 .69 , Ρ < .01) and the 
increases in P R A and A R were closely correlated (r = 
0 .96 , Ρ < . 001 ) . P lasma aldosterone was reduced by 
5 2 % from 178 ± 25 to 84 ± 8 p g / m L (P < .01) 9 0 min 
after the administration of captopril . 
I n f l u e n c e o f C G P 38 5 6 0 A o n B l o o d P r e s s u r e (F igure 
1) T h e dose of 0 .125 mg/kg of C G P 3 8 5 6 0 A induced a 
rapid fall in M A B P . T h e m a x i m u m decrease occurred 
be tween 20 and 30 min after administration (5 .7 ± 
2.2 m m Hg, Ρ < .05 ) . M A B P was back to basel ine 
TABLE 2. EFFECTS OF CAPTOPRIL ON BLOOD PRESSURE AND PLASMA RENIN 
1st Captopril Test 
Patients infused with Patients infused with 2nd Cantonril Te«st 
Time 0.125 mg/kg CGP 38 560A 0.250 mg/kg CGP 38 560A ^apiopr ies>t 
(min) n = 6 n = 6 n = 7* 
MABP PRA RA MABP PRA AR MABP PRA AR 
0 125.8 5.2 99 120.8 2.5 40 115.2 3.7 65 
± 5 . 6 (0 .6 -18 .1 ) ( 1 9 - 4 1 8 ) ± 6 . 0 (0 .3 -4 .3 ) ( 1 4 - 8 0 ) ± 3 . 1 (0 .2 -9 .9 ) ( 2 1 - 1 1 4 ) 
10 126.0 
± 6 . 4 
120.2 
± 6 . 1 
111.0 
± 3 . 9 
20 119.6t 
± 4 . 6 
115.2t 
± 6 . 3 
105.4:}: 
± 4 . 0 
30 115.4f 
± 4 . 7 
113.5t 
± 6 . 0 
102.0t 
± 2 . 9 
45 112.5t 
± 4 . 6 
108.7t 
± 7 . 3 
100.6:): 
± 2 . 4 
60 110.4t 
± 4 . 2 
109.4f 
± 7 . 7 
9 8 . l t 
± 2 . 5 
90 109.1J 36.2 533 106.8f 5.0 65 99.9φ 20.1 295 
± 4 . 3 (0 .7 -109 ) ( 2 3 - 2 2 4 0 ) ± 7 . 2 (0 .5 -11 .5 ) ( 2 0 - 1 0 3 ) ± 2 . 4 (0 .3 -77 .5 ) ( 1 7 - 9 1 5 ) 
* The 2nd captopril test was performed in 4 patients infused with 0.125 mg/kg and 3 patients infused with 0.250 mg/kg CGP 38 560A. 
Ϊ?<.05,$Ρ<.01. 
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FIGURE 1. Effects of CGP 28 560A on mean arterial blood 
pressure and pulse rate according to the dose. Empty squares 
(0.125mg/kg, η = 6), full squares (0.250 mg/kg, η = 6), *P < .05. 
3 0 min after the end of the renin inhibitor infusion. A 
similar fall in M A B P w a s observed (6 .0 ± 1 . 8 m m Hg, 
Ρ < .05) with the higher dose ( 0 . 2 5 0 mg/kg) . T h e fall 
remained significant until 15 min after the end of the 
infusion. T h e changes in systolic and diastolic b lood 
pressure were parallel. Pulse rate remained u n c h a n g e d 
with both doses. T h e m a x i m u m fall in M A B P was signif­
icantly correlated to the initial P R A (r = 0 . 6 1 , Ρ < .05 ) . 
I n f l u e n c e o f C G P 38 5 6 0 A o n t h e R e n i n A n g i o t e n s i n 
A l d o s t e r o n e S y s t e m ( T a b l e 3) P R A and A R were 
identical before captopril and C G P 3 8 5 6 0 A . With both 
doses of the renin inhibitor, P R A fell be low the detec­
tion limit in all patients be tween 10 and 4 5 min after 
starting the infusion. With the lowest dose P R A reap­
peared be t w e e n 4 5 and 60 min, whereas it remained 
undetectable with the 0 . 2 5 0 mg/kg dose up to 120 min 
after starting the infusion. P R A - T A returned towards 
basel ine earlier. It was inhibited by 5 7 % at 3 0 min after 
the end of the infusion of the lowest dose of the renin 
inhibitor, a n d b y 6 2 % 9 0 min after the end of the infu­
sion of the highest dose, a t ime w h e n P R A w a s still 
undetectable (Figure 2 ) . 
There were marked, stable, parallel falls in plasma 
A N G I and A N G II f rom 10 to 3 0 min after administra­
tion of the renin inhibitor. T h e fall in A N G I w a s greater 
with the higher dose ( 7 4 % after 0 . 1 2 5 mg/kg ν 9 4 % 
after 0 . 2 5 0 mg/kg, Ρ < .01 ) . Exactly the same result was 
found for A N G II levels, which fell b y 7 2 % and 9 4 % , 
respectively. Both A N G I and A N G II returned to their 
initial levels at 60 min with 0 . 1 2 5 mg/kg doses of renin 
inhibitor, while the levels remained lowered up to 
120 min fol lowing the higher dose (Figure 3 ) . T h e maxi­
m u m fall in M A B P was significantly correlated to the 
m a x i m u m fall in plasma A N G I (r = 0 .77 , η = 12, Ρ < 
.01) , a n d plasma A N G I a n d A N G II were significantly 
correlated to one another (r = 0 . 9 1 , η = 79 , Ρ < .001) . 
Active renin (AR) rose significantly with the 2 doses, 
on average by 3 6 6 % , reaching a peak at 4 5 min (15 min 
after the end of the infusion) (Table 3 ) . T h e n A R de­
creased progressively, remaining significantly above the 
pretreatment values at 120 min (P < .05 ) , and declining 
to the pretreatment values at 24 h (75 ± 2 1 , Ρ = NS) . 
N o dose dependency of the rise in A R could b e demon­
strated, but active renin levels after renin inhibitor were 
correlated to the initial active renin (r = 0 .82 , Ρ < .01). 
Figure 4 compares the percentage changes in plasma 
A N G II, M A B P and reciprocal active renin. It shows the 
parallelism of the t ime-course of events for these three 
variables. 
Similar variations in plasma aldosterone levels were 
observed with both doses. O n average, aldosterone de­
creased by 2 7 % to attain a m i n i m u m at 4 5 min (103 ± 
10 ν 142 ± 17 pg/mL, Ρ < . 01) , and then returned to its 
initial value. 
C o m p a r i s o n B e t w e e n C G P 38 5 6 0 A a n d Captopri l 
T h e fall in b lood pressure induced by captopril w a s sig­
nificantly correlated to that induced b y the renin inhibi­
tor (r = 0 .53 , η = 12, Ρ < .05) . In percentage, as well as 
in absolute values, the fall in b lood pressure w a s more 
marked 60 to 9 0 min after converting e nz ym e inhibition 
(13 .0 ± 4 . 3 % ) than after 3 0 min of renin inhibition 
(5 .3 ± 3 . 3 % , Ρ < . 001 ) . In addition, the fall in MABP 
b e c a m e significant (5 .8 ± 1.1 m m Hg, η = 12, Ρ < .05) 
20 min after captopril ingestion, and at 3 0 min it was 
already greater (8 .8 ± 2 .0 m m Hg, η = 12) than the fall 
in b lood pressure induced b y the renin inhibitor at 
3 0 min (5 .8 ± 1.4 m m Hg) . T h e M A B P w a s higher be-
1 i l l I I I I 
0 30 6 0 9 0 120 
FIGURE 2. Percentage falls in plasma angiotensin I (ANG 1) 
and plasma renin activity measured by the conventional PRA or 
by the ANG I trapping assay (PRA-TA). 
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FIGURE 3. Percentage falls in plasma angiotensins I (ANG I, 
η = 12) and II (ANG II, η = 10) according to the dose of CGP 38 
560A with empty (0.125 mg/kg) or full (0.250 mg/kg) diamond-
shaped points. 
fore captopril than before C G P 5 6 0 A infusion (123 ± 
4.0 ν 113.2 ± 3 .5 , η = 12, Ρ < .01 ) , probably because 
the captopril test was performed at an earlier stage of the 
patients' hospitalization. However , the 7 patients w h o 
had a second captopril test 24 h after the renin inhibitor 
infusion had pre-captopril b lood pressure values identi­
cal to those recorded before the renin inhibitor infusion 
(Table 2) . T h e decrease in M A B P observed after this 
second administration of captopril was still significantly 
greater (15.3 ± 3 m m Hg) than the fall in M A B P in­
duced by the infusion of the renin inhibitor (6.4 ± 
1.2 mm Hg, η = 7) . Active renin before captopril was 
very significantly correlated with active renin before 
CGP 38 5 6 0 A (r = 0 .92 , η = 12, Ρ < .001) , and the rise 
in active renin 9 0 min after captopril ingestion was also 
correlated to the m a x im um rise in active renin induced 
b y the renin inhibitor infusion (r = 0 .99 , η = 12 , Ρ < 
. 0 0 1 ) . 
D I S C U S S I O N 
T h e results of this initial investigation of the renin inhib­
itor C G P 3 8 5 6 0 A in hypertensive patients demonstrate 
that infusion of a renin inhibitor lowers b lood pressure 
in hypertensive patients w h o respond favorably to cap­
topril. This confirms both the medical concept a n d the 
validity of the methods used for the design a n d the 
selection of C G P 3 8 5 6 0 A . 5 T h e fall in b lood pressure 
occurs without an acceleration in heart rate at a dose 
which is ten times lower than that of H 1 4 2 , the first 
renin inhibitor which was injected in sodium-depleted 
heal thy v o l u n t e e r s . 1 5 T h e rapid fall in b lood pressure 
be tween 0 and 10 min and its return to initial values are 
strictly in parallel with the fall in, and the reappearance 
of, circulating A N G I and A N G II. Because these p a ­
tients were selected on the basis of a fall in b lood pres­
sure after captopril ingestion, they h a d a renin-depen-
dent form of hypertension, which explains w h y the fall 
in b lood pressure is correlated to the fall in plasma A N G 
I and A N G II. T h e dose-dependency easily detected in 
the plasma A N G I and A N G II measurements was not 
found in the blood pressure. This shows that the b io ­
chemical p h e n o m e n o n — r e n i n i n h i b i t i o n — i s opti­
mally investigated b y the measurement of these pep­
tides, whereas the clinical consequence of renin 
inhibition, the fall in b lood pressure, is only partially 
dependent on renin inhibition. It depends on the contri­
bution of the renin-angiotensin system to the mainte ­
nance of b lood pressure in each patient, which m a k e s it 
difficult to build dose-response curves on b lood pres­
sure with a small n u m b e r of patients. 
T h e rise and then the fall in the A R in the plasma 
during renin inhibition occurred slightly after the 
changes in plasma A N G I and A N G II a n d the subse­
quent changes in b lood pressure. W h e r e a s dose-depen­
dent suppression of both A N G I and A N G II reached its 
nadir during C G P 3 8 5 6 0 A infusion, the increase in A R 
in the plasma, reached its zenith 15 min later, which 
reflects the longer plasma half- l i fe of renin compared 
with angiotensins. 
T h e rise in A R was not dose-dependent . T h e magni ­
tude of the reactive renin release is characteristic for 
each individual, as suggested b y the very significant 
correlation be tween the changes in A R after captopril 
and C G P 3 8 5 6 0 A . As the blood pressure falls, these 
changes in A R were extremely variable f rom one patient 
to the other, and a possible influence of the renin inhibi­
tor dose was blunted by other predominant factors such 
as the initial rate of renin release and renin synthesis , 
processing and storage in the juxtaglomerular cells. 
This study raises two challenging questions: w h y do 
P R A and the decrease in b lood pressure dissociate after 
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FIGURE 4. Effects of CGP 38 560A on mean arterial blood 
pressure (MABP, square), angiotensin II (ANG II, diamond-
shaped) and active renin (AR, circle). The results are expressed in 
percent of the control value. 
renin inhibition, and w h y is captopril more hypotensive 
than CGP 38 5 6 0 A ? Apparently, this clinical investiga­
tion of a renin inhibitor in hypertensive patients con­
firms the observation m a d e in a n i m a l s 3 , 4 and, in a pre­
liminary report, in hypertensive patients injected with 
the renin inhibitor A 6 4 6 6 2 . 1 6 T h e in vitro inhibition of 
plasma renin activity is dissociated f rom the changes in 
blood pressure after administration of a renin inhibitor 
and blood pressure returns towards its initial value de­
spite a much more prolonged in vitro suppression of 
plasma renin activity. Another kind of dissociation was 
also previously observed, be tween plasma A N G II 
levels and P R A in heal thy volunteers on a normal so­
dium intake. A long-lasting suppression of P R A m e a ­
sured by a conventional m e t h o d was present for 
150 min after the end of this renin inhibitor infusion, 
despite a normalization of plasma A N G I I . 6 In another 
investigation, the same doses of this renin inhibitor were 
infused in normal volunteers after a mild sodium deple­
tion induced by furosemide 4 0 m g . 7 P lasma A N G II was 
measured by the same m e t h o d as in the previous exper­
iment,1 4 but P R A was investigated by the A N G I trap­
ping assay. 7 T h e inhibition of P R A - T A was m u c h 
shorter than the inhibition of P R A observed in the vol­
unteers not subjected to sodium restriction. However , it 
was still present 9 0 min after the end of the renin- inhib-
itor infusion, whereas A N G II levels returned to their 
initial values at 30 min. 
In the present investigation, we demonstrate that the 
two PRA methods used in parallel to investigate in vitro 
ANG I generation provide results different f rom the in 
vivo measurements. P lasma A N G I, the immediate 
product of the in vivo renin reaction, plasma A N G II, the 
active peptide, and blood pressure returned to the vicin­
ity of their initial values before P R A measurements . T h e 
conventional measurement of P R A grossly overesti­
mated the in vivo duration of action of the renin inhibi­
tor, whereas the P R A - T A came m u c h closer to plasma 
A N G values, a l though it still differed. W e conclude that 
the conventional m e t h o d of P R A measurement is not 
appropriate for quantifying the in vivo renin inhibition. 
This conclusion is not exclusive to C G P 3 8 5 6 0 A and 
m a y also be true for other renin inhibitors synthesized 
according to a similar a p p r o a c h . 1 , 1 6 ' 1 7 
T h e second challenging observation is the small fall in 
b lood pressure under C G P 3 8 5 6 0 A compared with that 
observed under captopril, despite a dramatic fall in 
plasma A N G I and plasma A N G II. Al though the com­
parison of the oral administration of a converting en­
zyme inhibitor with the intravenous infusion of a renin 
inhibitor is difficult to make , and was not in fact the 
initial goal of this investigation, it is certainly an impor­
tant observation. T h e fall in M A B P during renin inhibi­
tion by C G P 3 8 5 6 0 A was less than the fall induced by 
the single oral administration of 5 0 mg captopril, a dose 
which is widely used to investigate the role of the renin 
angiotensin system in hypertensive pat ients . 8 This dif­
ference was not dependent on the level of M A B P before 
the t e s t , 1 8 since it is also observed in the 7 patients w h o 
h a d a second captopril test, and w h o at this t ime h a d the 
same initial levels of M A B P before converting e nz ym e 
inhibition as prior to renin inhibition. This observation 
contrasts with the results previously obtained in mar­
mosets . T h e magnitude of the fall in b lood pressure 
induced by a renin inhibitor ( G G P 29 2 8 7 ) was similar to 
the fall induced b y a converting e nz ym e inhibitor (te-
p r o t i d e ) , 1 9 which suggested that the two types of inhibi­
tion were equally effective on b lood pressure. 
T h e more pronounced effect of the ACE-inhibi tor , 
compared with the renin inhibitor, could be due to a 
biochemical effect such as bradykinin accumulation, in 
addition to exclusive A N G II suppression. S u c h a bra­
dykinin accumulat ion might add its o w n antihyperten­
sive effect, directly or through prostaglandin synthesis , 
on top of the hypotension induced b y A N G II suppres­
s i o n . 2 0 However , recent animal experiments have chal ­
lenged this h y p o t h e s i s . 2 1 
Another explanation, within the renin angiotensin 
system, would b e a difference in the degree of the 
blockade achieved by the two different inhibitors of the 
renin-angiotensin system at the selected doses. Accord­
ing to our observations on the limitations of in vitro 
A N G I generation in the presence of a renin inhibitor, 
the in vitro potency of C G P 3 8 5 6 0 A m a y have been 
overestimated, which might explain w h y the full effi­
cacy of renin inhibition could not b e obtained with this 
compound, despite circulating levels of C G P 3 8 5 6 0 A 
theoretically more than 1 0 0 0 times higher than the cal­
culated K x (0 .4 n m o l ) . 5 - 2 2 In the 10 patients evaluated, 
A N G II levels fell to values be low 1 f m o l / m L during 
infusion of C G P 3 8 5 6 0 A in only 6 subjects, while in the 
other 4 the A N G II levels remained at peak renin inhibi-
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tion be tween 1.1 and 6.0 fmol/mL, despite an important 
decrease of 6 5 - 9 3 % from pre- infusion values. These 
results are at variance with the low unmeasurable levels 
which were observed in all heal thy volunteers tested 
previously with 25 mg intravenous captopr i l . 2 3 It is 
therefore possible that plasma A N G II was less sup-
pressed after the infusion of the renin inhibitor at the 
doses selected than after A C E inhibition. A definite 
conclusion is not possible since plasma A N G II was not 
measured during the initial captopril test, which w a s 
only used to screen renin-dependent hypertension, and 
moreover , the discriminatory power of plasma A N G II 
measurements at these low levels m a y still need to b e 
improved. 
Conceivably , a ma jor fall in A N G I and A N G II levels 
in plasma, a l though necessary, m a y not be sufficient to 
adequately explain the magnitude of the fall in b lood 
pressure due to a blockade of the renin-angiotensin sys-
tem. T h e inhibition of the angiotensin I converting en-
zyme, which is mostly immobil ized on the endothelial 
cells and produces A N G II near to its receptors on the 
vascular smooth muscle cells, might have more effect on 
the b lood pressure than the inhibition of the renin circu-
lating in the plasma compartment . To b e optimally ef-
fective, renin inhibit ion might require a more complete 
suppression of A N G I generation at additional plasma 
sites, such as the interstitial space, where both renin a n d 
angiotensinogen are p r e s e n t . 2 4 , 2 5 Therefore , our results 
should not b e extrapolated to renin inhibition in general 
a n d are certainly dependent on the characteristics of this 
class of renin inhibitor, represented b y C G P 3 8 5 6 0 A . 
C G P 3 8 5 6 0 A is strongly b o u n d to plasma proteins a n d 
its vo lume of distribution m a y not al low for a sufficient 
diffusion to the in vivo production sites of A N G I in the 
interstitial space. Other renin inhibitors, more potent , 
less prote in-bound and less rapidly metabol ized are 
needed in order to k n o w if an additional fall in b lood 
pressure might occur b e y o n d that induced b y the fall in 
plasma angiotensins. 
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